MarianoPardo @MarianoPardo: "$VEEV is up 8.7% after..."

Malta

$VEEV (Veeva Systems Inc A) is up 8.7% after reporting earnings. Let's dive into the results: Veeva just reported its Q2 FY2025 earnings, and the results were quite strong, with total revenues reaching $676.2 million, a 15% increase year-over-year. Subscription services, which make up the bulk of Veeva's revenue, grew by 19% to $561.3 million. Non-GAAP operating income came in at $279.8 million, marking a 32% increase from the previous year. This growth was driven by continued success in Veeva's Development Cloud and Commercial Cloud, with significant new customer wins, especially in the biopharma sector. Notably, the company signed a large deal with a top 20 biopharma for its Veeva Development Cloud. Additionally, Veeva's advancements in AI through its AI Partner Program and Vault Direct Data API are beginning to show promise, positioning the company to drive further innovation in data integration and automation. The company's product strategy is also gaining traction, with key innovations such as the new release of Veeva Site Connect and Veeva Clinical Database (CDB) designed to streamline clinical trials and data management for biopharma clients. These innovations are not only winning new customers but also strengthening relationships with existing ones. For example, Veeva's Clinical Database has been adopted by seven top 20 biopharma companies to enhance data collection and cleaning, resulting in significant cost savings and efficiency gains. In the Commercial Cloud segment, the release of the Vault CRM Service Center and strong execution in Crossix further underscore the company's capacity to drive value for life sciences companies through integrated sales, marketing, and data solutions. Looking ahead, Veeva has set its guidance for Q3 FY2025 with projected revenues between $682 million and $685 million and non-GAAP operating income of $273 to $275 million. The company remains focused on leveraging its cloud-based platforms to drive growth across both R&D and commercial operations within the life sciences sector. With a strong product pipeline, continuous innovation, and a clear strategic vision, Veeva is well-positioned to capitalize on the growing demand for digital transformation solutions in this industry. The company's robust financials and ongoing product advancements suggest a favorable outlook. The integration of AI capabilities within its platforms is expected to further enhance Veeva's offerings, driving more value for its customers and potentially increasing its revenue per customer.

1 Mentioned

VEEV

Veeva Systems Inc A